Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women

Obstetrics and Gynecology

Volumn 96, Issue 4, 2000, Pages 521-528

  Kurabayashi, Takumi ^a   Okada, Masahiko ^a   Tanaka, Kenichi ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CREATINE KINASE; ESTRIOL; FAS ANTIGEN; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; EPISTAXIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; JAPAN; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

APOLIPOPROTEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EICOSAPENTAENOIC ACID; ESTRIOL; FEMALE; HUMANS; HYPERLIPIDEMIAS; MENOPAUSE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 0033833730     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)00988-1     Document Type: Article

References (45)

1. Matthews K.A., Meilahn E., Kuller L.H., Kelsey S.F., Caggiula A.W., Wing R.R. Menopause and risk factors for coronary heart disease. N Engl J Med. 321:1989;641-646.
2. Campos H., McNamara J.R., Wilson P.W., Ordovas J.M., Schaefer E.J. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 67:1988;30-35.
3. Stevenson J.C., Crook D., Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 98:1993;83-90.
4. Brunner D., Weisbort J., Meshulam N., Schwartz S., Gross J., Saltz-Rennert H., et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events Twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study . Am J Cardiol. 59:1987;1271-1276.
5. Castelli W.P. The triglycerides issue A view from Framingham . Am Heart J. 112:1986;432-437.
6. Bass K.M., Newschaffer C.J., Klag M.J., Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular deaths in women. Arch Intern Med. 153:1993;2209-2216.
7. Simpson H.C., Mann J.I., Meade T.W., Chakrabarti R., Stirling Y., Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet. 1:1983;786-790.
8. Miller G.J., Martin J.C., Webster J., Wilkes H., Miller N.E., Wilkinson W.H., et al. Association between dietary fat intake and plasma factor VII coagulant activity - A predictor of cardiovascular mortality. Atherosclerosis. 60:1986;269-277.
9. Oseroff A., Krishnamurti C., Hassett A., Tang D., Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med. 113:1989;88-93.
10. Lobo E.A. Effect of hormone replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 73:1991;925-930.
11. Muesing R.A., Miller V.T., LaRosa J.C., Stoy D.B., Phillips E.A. Effect of unopposed conjugated equine estrogen on lipoprotein composition and apolipoprotein-E distribution. J Clin Endocrinol Metab. 75:1992;1250-1254.
12. Granfone A., Campos H., McNamara J.R., Schaefer M.M., Lamon-Fava S., Ordovas J.M., et al. Effect of estrogen replacement on plasma lipoproteins and apoproteins in postmenopausal, dyslipidemic women. Metabolism. 41:1992;1193-1198.
13. Whitcroft S.I., Crook D., Marsh M.S., Ellerington M.C., Whitehead M.I., Stevenson J.C. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol. 84:1994;222-226.
14. Lafferty F.W., Fiske M.E. Postmenopausal estrogen replacement A long-term cohort study . Am J Med. 97:1994;66-77.
15. Hulley S., Grady D., Bush T., Furberg C., Herrington D.B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
16. Wilson P.W., Garrison R.J., Castelli W.P. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med. 313:1985;1038-1043.
17. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
18. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
19. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 325:1991;1196-1204.
20. Bang H.O., Dyerberg J., Nielsen A.B. Plasma lipid and lipoprotein pattern in Greenlandic west-coast Eskimos. Lancet. 1:1971;1143-1145.
21. Dyerberg J., Bang H.O., Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr. 28:1975;958-966.
22. Needleman P., Minkes M., Raz A. Thromboxanes Selective biosynthesis and distinct biological properties . Science. 193:1976;163-165.
23. Dyerberg J., Bang H.O., Stoffersen E. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 2:1978;117-119.
24. Needleman P., Raz A., Minkes M.S., Ferrendelli J.A., Sprecher H. Triene prostaglandins Prostacyclin and thromboxane biosynthesis and unique biological properties . Proc Natl Acad Sci U S A. 76:1979;944-948.
25. Harris W.S. Fish oils and plasma lipid and lipoprotein metabolism in humans A critical review . J Lipid Res. 30:1989;785-807.
26. Gries A., Malle E., Wurm H., Kostner G.M. Influence of dietary fish oils on plasma Lp(a) levels. Thromb Res. 58:1990;667-668.
27. Nozaki S., Matsuzawa Y., Hirano K., Sakai N., Kubo M., Tarui S. Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia. Int J Vitam Nutr Res. 62:1992;256-260.
28. Nakamura N., Hamazaki T., Ohta M., Okuda K., Urakaze M., Sawazaki S., et al. Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res. 29:1999;22-25.
29. Friedewald W.T., Levy R.I., Fredrick D.S. Estimation of the concentration of low density lipoprotein in plasma without use of a preparative ultracentrifuge. Clin Chem. 18:1972;449-456.
30. Vaisanen S., Gavert J., Julkunen A., Voutilainen E., Penttila I. Correlation between the ratio of serum low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with that of serum apolipoprotein B and A-I. Int J Clin Lab Res. 23:1993;160-164.
31. Shiozaki K., Kambayashi J., Kawasaki T., Uemura Y., Sakon M., Shiba E., et al. The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease. J Atheroscler Thromb. 2:1996;107-109.
32. Hayashi K., Ohtani H., Kurushima H., Nomura E., Koide K., Kunita T., et al. Decreases in plasma lipid content and thrombotic activity by ethyl icosapentate purified from fish oils. Curr Ther Res. 56:1995;24-31.
33. Mizuguchi K., Yano T., Ishibashi M., Masada A., Mizota M., Saito Y. Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein. Eur J Pharmacol. 235:1993;221-227.
34. Mizuguchi K., Yano T., Tanaka Y., Ishibashi M., Masada A., Mizota M., et al. Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate. Eur J Pharmacol. 231:1993;121-127.
35. Haarbo J., Hassager C., Riis B.J., Christiansen C. Relation of body fat distribution to serum lipids and lipoproteins in elderly women. Atherosclerosis. 80:1989;57-62.
36. Soler J.T., Folsom A.R., Kaye S.A., Prineas R.J. Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin, and estrogen with lipids and lipoproteins in post-menopausal women. Atherosclerosis. 79:1989;21-27.
37. Esposito G. Estriol A weak estrogen or a different hormone? Gynecol Endocrinol. 5:1991;131-153.
38. Molander U., Milsom I., Ekelund P., Mellström D., Eriksson O. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. Maturitas. 12:1990;113-120.
39. Minaguchi H., Uemura T., Shirasu K., Sato A., Tsukikawa S., Ibuki Y., et al. Effect of estriol on bone loss in postmenopausal Japanese women A multicenter prospective open study . J Obstet Gynaecol Res. 22:1996;259-265.
40. Tzingounis V.A., Aksu M.F., Greenblatt R.B. Estriol in the management of the menopause. JAMA. 239:1978;1638-1641.
41. Hauser H.P., Staemmler H.J. Histological investigations into the effect of oestriol succinate on the corpus uteri in postmenopausal women. Arzneimittelforschung. 23:1973;558-562.
42. Salmi T. Endometrial carcinoma risk factors, with special reference to the use of estrogens. Acta Endocrinol (Copenh). 233:(Suppl):1980;37-43.
43. Persson I., Adami H.O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens Results of a prospective study . BMJ. 298:1989;147-151.
44. Schairer C., Adami H.O., Hoover R., Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology. 8:1997;59-65.
45. Weiderpass E., Baron J.A., Adami H.O., Magnusson C., Lindgren A., Bergström R., et al. Low-potency oestrogen and risk of endometrial cancer A case-control study . Lancet. 353:1999;1824-1828.